EA.hy926 Umbilical Vein Endothelial Cells Clone A549 (EA.hy926)

EA.hy926 cell line is a widely used and established human endothelial cell line that was created by fusing primary human umbilical vein endothelial cells (HUVECs) with the A549 lung adenocarcinoma cell line. The EA.hy926 cell line was developed in the 1990s by Dr. Edgell's laboratory at the University of North Carolina.

The fusion of HUVECs with A549 cells resulted in the EA.hy926 cell line, which displays characteristics of both endothelial cells and cancer cells. The EA.hy926 cells retain many of the typical endothelial cell properties, including the ability to form capillary-like structures, respond to angiogenic factors, and express specific endothelial cell markers.

The EA.hy926 cell line has gained popularity in research due to its versatility and properties that mimic normal endothelial cells. Researchers use EA.hy926 cells to study various aspects of vascular biology, including endothelial cell function, angiogenesis, blood-brain barrier permeability, inflammation, and vascular-related diseases such as atherosclerosis and cancer.